title: [Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS].
abstract: OBJECTIVE
  To study the curative effect of HAG and CAG regimens for patients with acute myelocytic leukemia (AML) and high/medium-risk myelodysplastic syndrome (MDS).
  
  
  METHODS
  Fifty two patients from January 2010 to January 2014 were enrolled in this study, 32 were diagnosed with AML and 20 with MDS. All the patients were divided into 2 groups: 26 in HAG group (26 cases) and another 26 in CAG group (26 cases). The bone marrow examination, remission rate, PFS, OS and side reaction rates were compared between 2 groups.
  
  
  RESULTS
  After treatment, the bone marrow hyperplasia and juvenile cells were decreased significantly. In HAG group, the remission rate was 57.69% and that was 76.92% in CAG group, the difference between these 2 groups was statistically significant (P<0.05), but the survival time was not statistically significant different between 2 groups (P>0.05). The incidence of side reaction in HAG group was 11.54%, that in CAG group was 7.69%, there was no statistically significant difference (P>0.05).
  
  
  CONCLUSIONS
  Both CAG and HAG regimens have shown significant curative effects for acute myelocytic leukemia and high/medium-risk myelodysplastic syndrome.
authors.affiliation: Department of Hematology, Miners Group General Hospital of Anhui Huaibei, Huaibei 235000, Anhui Province, China. E-mail: zhu2824170586@sina.com.
authors.forename: Yi-Nan
authors.initials: YN
authors.lastname: Zhu
authors.affiliation: Department of Hematology, Miners Group General Hospital of Anhui Huaibei, Huaibei 235000, Anhui Province, China.
authors.forename: Xue-Fei
authors.initials: XF
authors.lastname: Yang
authors.affiliation: Department of Hematology, Miners Group General Hospital of Anhui Huaibei, Huaibei 235000, Anhui Province, China.
authors.forename: De-Zhen
authors.initials: DZ
authors.lastname: Wang
authors.affiliation: Department of Hematology, Miners Group General Hospital of Anhui Huaibei, Huaibei 235000, Anhui Province, China.
authors.forename: Zhan-Wei
authors.initials: ZW
authors.lastname: Liu
mesh_terms: D015250:Aclarubicin / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001856:Bone Marrow Examination; D003561:Cytarabine / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin